Swift Biosciences Launches Unique Dual Indexing Kits to Improve Multiplexed Next Generation Sequencing

Food and Healthcare Press Releases Monday April 9, 2018 09:50
ANN ARBOR, Michigan--9 Apr--PRNewswire/InfoQuest
  • New Accel-NGS Unique Dual Indexing Kits minimize read misassignments for higher quality results

Swift Biosciences today announced the launch of its Accel-NGS(R) Unique Dual Indexing Kits , which deliver the power and value of high-throughput multiplexed sequencing while improving the accuracy of low frequency variant calling, such as somatic mutations, in samples such as FFPE and cfDNA.

Multiplexed sequencing is a commonly used technique among clinical research, drug development and clinical services labs utilizing next-generation sequencing (NGS). The Accel-NGS Unique Dual Indexing Kits are an essential addition to NGS workflows, as current tools can suffer from demultiplexing problems caused by index read errors, PCR-induced chimerism associated with multiplexed hybridization capture workflows, and index hopping on patterned flow cells.

Swift's Accel-NGS Unique Dual Indexing Kits, developed in a set of 96 dual indices for both i7 and i5 positions, provide a more scalable and reliable workflow for a range of applications including:
  • Low-frequency somatic variant discovery
  • Formalin-fixed paraffin-embedded analysis
  • Microbial detection in human samples
  • Cell-free DNA analysis

"By directly addressing read misassignments we are providing a more accurate solution which could open up new applications, such as tumor mutation burden profiling," said Candia Brown, Swift's Vice President of Global Marketing.

Key features and benefits of the Accel-NGS Unique Dual Indexing Kits include:
  • Optimized across all Illumina sequencing instruments
  • Improves misassignment rates to less than 0.1 percent
  • Enables multiple applications including whole genome sequencing, whole exome and methylation analysis
  • Compatibility with Swift library prep kits including Accel-NGS 1S, Accel-NGS 2S, and Accel-NGS Methyl-Seq

"Swift's unique dual indices provide higher confidence in calling low frequency variants and maintains data quality as sequencing throughput and multiplexing capability continue to increase," said Laurie Kurihara, PhD, Swift's Vice President of Product Development.

The new indexing kits are specifically designed and compatible for any Illumina platform and are now commercially available.
About Swift Biosciences

Swift Biosciences is the NGS Library Prep company. Based in Ann Arbor, Michigan, the company develops novel library preparation solutions for emerging applications based on next-generation sequencing, including whole genome sequencing, targeted DNA sequencing, and epigenetic analysis. Swift Biosciences' products are designed to help customers analyze challenging biological samples faster, easier, and with greater sensitivity and accuracy, while being compatible with leading instrumentation. Swift Biosciences is the first company to offer library preparation solutions on all three major sequencing platforms, including Pacific Biosciences(R), Illumina(R) and Ion Torrent(TM).

The company opened its doors in February 2010, and its product development enables new applications in multiple industries, including agrigenomics, pharmaceutical, academic, biotechnology, and oncology research fields.

For more information, visit   SwiftBioSci.com and follow Swift Biosciences on Twitter (@SwiftBioSci).

Latest Press Release

Boehringer Ingelheim has a very successful 2017 financial year

- Sharp increase in net sales to nearly 18.1 billion euros (+15.7 per cent in currency-adjusted terms; +13.9 per cent in euro terms) - Operating income rises significantly to around 3.5 billion euros - Return on net sales of 19.3 per cent - Strengthened...

Merck Receives Patent for CRISPR Technology in China

- Patent in China covers integration of an external DNA sequence into the chromosome of eukaryotic cells - Company to license CRISPR-related patents to interested parties, supports genome-editing research under ethical and legal standards -...

Cell and Gene Therapy Catapult Opens Manufacturing Centre to Accelerate Growth of the Industry in the UK

- Centre will 'bridge the gap' between scientific research and commercialisation of the medicines of the future - Over GBP60 million of Industrial Strategy investment is being used to develop the new centre Today,the Cell and Gene Therapy Catapult's...

Creation of Inceptua Clinical Trial Services Marks New Era for the Company

Inceptua Group (previously Multipharma) today announces that its Clinical Trial Supplies business unit is rebranding to Inceptua Clinical Trial Services. Going forward, all of the group's three business units including Clinical Trial Services, Medicines...

FDI White Paper and Practical Guide Address the Global Burden of Periodontal Disease

FDI World Dental Federation published two resources - a white paper and a practical guide - as part of its Global Periodontal Health Project (GPHP), which aims to bring attention to periodontal health as a priority area for policy worldwide. (Logo:...

Related Topics